treatments · European Union · Regulatory recommendation with subsequent authorisation update
Cenrifki: April recommendation followed by June EU authorisation
European Medicines Agency · published 2026-04-24 · approved by our editors 9/7/2026
EMA’s committee recommended Cenrifki, containing tolebrutinib, for adults with non-relapsing secondary progressive MS. This April report describes a recommendation; EMA’s later medicine record confirms EU authorisation on 19 June 2026. That current record includes liver-monitoring requirements.
What this means
The current EU indication is for adults with secondary progressive MS without relapses in the preceding two years. The recommendation and authorisation have different dates.
Read the original
This is our short summary. The full article belongs to European Medicines Agency (regulator).
Read the original articleMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2026